Prolog Ventures

What Prolog Ventures does

Prolog Ventures is a St. Louis-based venture capital firm founded in the 1990s that invests exclusively in early-stage startups operating at the intersection of health, wellness, sustainable food, and medical/agricultural technology. The firm manages a portfolio of 100+ companies over its history, with active holdings spanning premium beverages (Spindrift), on-demand wellness services (Zeel), disinfection technology (Kinnos), precision diagnostics (Moleculera Biosciences), brain-computer interface rehabilitation (Neurolutions IpsiHand), plant genomics (Benson Hill CropOS), sustainable cover crops (CoverCress), and clinical-stage vaccines (Sequoia Vaccines).

The firm's core 'product' is equity capital paired with board-level strategic guidance delivered by a five-partner team whose members previously operated and exited companies at Monsanto, Alcon, Boston Consulting Group, Megan Health, ShopWell, and ThinOptics, and who collectively hold 25-30+ years of venture investing experience. Prolog generates returns through capital appreciation on direct equity investments; realized exits include the Benson Hill SPAC IPO on NYSE at $2B valuation (2021), Veran Medical to Olympus for up to $340M (2020), NxThera to Boston Scientific for $306M upfront plus up to $100M earn-out (2018), Spindrift majority stake to Gryphon Investors (2025), CoverCress majority to Bayer (2022), and smaller divestitures to Boston Scientific, Sartorius, Campbell, Post Foods, Peet's Coffee, and Monsanto.

The firm's go-to-market is relationship-driven deal sourcing within its 'healthy living' thesis, supported by a website portfolio showcase, LinkedIn and Twitter presence, and earned media coverage of portfolio milestones. Fund management fees and carried interest are not publicly disclosed, consistent with private partnership norms.

Name

Prolog Ventures

Legal name

Prolog Ventures

Website

https://prologventures.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Prolog Ventures is a St. Louis-based venture capital firm, founded in the 1990s, that backs early-stage startups in health, wellness, food technology, medical devices, and sustainable agriculture, having partnered with 100+ companies over its history.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

akta.pro secondary industries

Healthcare & Life Sciences Growth Equity (FSANACAB), Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Venture capital investing
• Early-stage health startups
• Healthy living investments
• Life sciences funding
• Wellness sector capital

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. VC Fund Management: Prolog Ventures generates returns through equity investments in portfolio companies. The firm earns returns when portfolio companies achieve successful exits via IPOs or acquisitions. Notable exits include Spindrift (majority stake sale to Gryphon Investors), CoverCress (majority stake to Bayer), Benson Hill (IPO on NYSE), Veran (acquired by Olympus for up to $340M), Veniti (acquired by Boston Scientific), IntelliCyt (acquired by Sartorius), and others.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Prolog Ventures is a venture capital firm that invests equity capital in early-stage startups focused on healthy living, including food and beverage, wellness services, medical devices, infection prevention, and agricultural technology. The firm provides not only funding but also board-level strategic guidance, industry connections, and operational expertise drawn from partners who have previously founded and exited companies themselves.

Product overview

Prolog Ventures is a venture capital firm focused on startups supporting healthy lives in a healthy world. The firm manages a diversified portfolio of companies across health, wellness, food technology, and agriculture sectors. Current portfolio companies include Spindrift (premium sparkling water with real fruit), Zeel (on-demand massage therapy platform), Kinnos Highlight (color additive disinfection platform), Moleculera Biosciences (precision medicine for CNS disorders), Neurolutions IpsiHand (brain-computer interface for stroke rehabilitation), Benson Hill (plant-based food technology with CropOS platform), CoverCress (low carbon cover crop for biofuels), and Sequoia Vaccines (urinary tract infection vaccine). The portfolio also includes multiple successfully acquired companies including Plum Organics, Attune Foods, Divergence, IntelliCyt, Veran, VENITI, NxThera, and Revive Kombucha, as well as Benson Hill which went public through a SPAC merger.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-stage venture capital investment (healthy living thesis) Equity investment capital paired with board-level strategic guidance and operational expertise, provided to early-stage startups in healthy living sectors (food/beverage, wellness, medical devices, agricultural technology). The firm's partners directly lead or participate in funding rounds and serve on portfolio company boards.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered strategic, core, support and regional.

• Dave Burwick (CEO Appointment)strategicOthers · 14 January 2025As part of the Gryphon Investors acquisition of Spindrift, experienced CPG executive Dave Burwick was appointed as new CEO, with founder Bill Creelman transitioning to chairman.
• BioSymetricsstrategicStrategic or Co-development Partner · 1 October 2024BioSymetrics and Moleculera partnered to advance personalized treatment for immune-mediated neuropsychiatric disorders, combining AI and diagnostic capabilities.
• Quest DiagnosticscoreStrategic or Co-development Partner · 17 January 2024Moleculera Labs formed a strategic collaboration with Quest Diagnostics to broaden access to its neuropsychiatric autoantibody testing services, expanding reach of diagnostic capabilities.
• Kandu HealthstrategicStrategic or Co-development Partner · 8 November 2023Neurolutions and Kandu Health announced a strategic partnership to accelerate access to breakthrough brain computer interface technology and remote support for stroke rehabilitation.
• Massage Magazine Insurance PlussupportChannel Partner/ Reseller/ Distributor · 5 June 2023Zeel partnered with Massage Magazine Insurance Plus to expand insurance coverage to Zeel massage professionals, enhancing professional liability protection for therapists on the platform.
• Veterans Administration Community CarecoreStrategic or Co-development Partner · 1 May 2023The Veterans Administration Community Care program approved Zeel to connect massage therapists with U.S. military veterans, providing non-opioid pain relief options.
• Armstrong Medical SupplysupportChannel Partner/ Reseller/ Distributor · 1 May 2023Kinnos partnered with Armstrong Medical Supply to benefit veterans through expanded distribution of Highlight disinfection products.
• Fraser HealthregionalChannel Partner/ Reseller/ Distributor · 31 January 2023Fraser Health region implemented Kinnos Highlight disinfection system across hospitals, including Langley Memorial Hospital, for improved infection control.
• General GenomicscoreStrategic or Co-development Partner · 26 July 2022Moleculera Labs and General Genomics formed a strategic alliance to utilize proprietary AI to provide personalized medicine for autoimmune neuropsychiatric disorders.
• New York City Vaccine Command CenterstrategicStrategic or Co-development Partner · 27 May 2021Zeel's partnership with NYC Vaccine Command Center expanded in-home vaccinations to anyone over 75, all disabled, and under-vaccinated buildings during the COVID-19 pandemic.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Genoa Ventures: Genoa Ventures is an early-stage venture firm investing in biotech, health tech, and wellness companies. Comparable to Prolog in stage, fund size, and life-sciences/health thematic focus.
• ARCH Venture Partners: ARCH is an early-stage venture firm with deep life sciences, biotech, and health-tech focus. Comparable to Prolog in its early-stage thesis and science-driven portfolio, though ARCH operates at meaningfully larger fund sizes.
• Lux Capital: Lux Capital invests in early-stage science and technology ventures including health, biotech, and sustainability. Similar to Prolog in its early-stage, founder-focused approach with domain expertise across health-adjacent verticals.
• Santé Ventures: Santé Ventures is a healthcare and life sciences focused early-stage venture firm. Directly comparable to Prolog in stage, sector focus, and check size within medical devices, biotech, and health services.
• Aperture Venture Partners: Aperture is a small, sector-focused early-stage investor in digital health, medical devices, and health services. Comparable to Prolog in fund size, sector concentration, and stage preference.
• Forerunner Ventures: Forerunner invests early in consumer-focused health, wellness, and food/beverage companies. Comparable to Prolog in backing health-and-wellness consumer brands (e.g., Spindrift-style CPG).
• Cultivian Sandbox Ventures: Cultivian Sandbox is a Midwest-based venture firm focused on food, agriculture, and animal health technology. Comparable to Prolog in its Midwest base and food/agtech/health investment thesis (e.g., Benson Hill, CoverCress).

Broad incumbents

• Andreessen Horowitz (a16z Bio + Health): a16z's Bio + Health fund invests across healthcare, biology, and health-tech. Comparable to Prolog in health-and-wellness thesis but at substantially larger fund size and broader mandate.
• Khosla Ventures: Khosla Ventures is a large, established venture firm with significant health, food, and sustainability exposure. Comparable in thematic focus but operates at much larger fund scale with broader sector reach.
• Flagship Pioneering: Flagship Pioneering is an established life-sciences innovation firm creating and backing breakthrough health and biotech companies. Comparable to Prolog in health/biotech thesis, though Flagship operates at substantially larger scale with internal venture creation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/PrologVentures
• LinkedInlinkedin.com/company/prolog-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments72 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolog Ventures